Mandelia Ashish 的 Form 4/A 修正申報
修正Mersana Therapeutics, Inc.（MRSN），2024/2/16 申報
- 申報編號
- 0001104659-24-024929
- 申報時間
- 2024/2/16
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2024/1/17
這份申報沒有列出任何交易。沿用原件裡沒有重述的 11 筆交易。公開市場賣出合計 $1.36 萬。
這份修正申報重述了 0001104659-24-004549（2024/1/17 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Mandelia AshishCIK 0001782805 | 高階主管（副總裁、會計主管） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001104659-24-004549（2024/1/17 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/1/13 | Common Stock | M行使選擇權取得 | +2,645 | $0.00 | $0 | 18,218 | 直接 | |
| 2024/1/14 | Common Stock | M行使選擇權取得 | +4,783 | $0.00 | $0 | 23,001 | 直接 | |
| 2024/1/15 | Common Stock | M行使選擇權取得 | +4,519 | $0.00 | $0 | 27,520 | 直接 | |
| 2024/1/15 | Common Stock | M行使選擇權取得 | +833 | $0.00 | $0 | 28,353 | 直接 | |
| 2024/1/16 | Common Stock | S賣出處分 | −5,025 | $2.71F7 | −$13,617.75 | 23,328 | 直接 |
衍生性證券（表 II）
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/1/13 | Common Stock | M行使選擇權處分 | −2,645 | $0.00 | $0 | 7,938 | 直接 | |
| 2024/1/14 | Common Stock | M行使選擇權處分 | −4,783 | $0.00 | $0 | 9,566 | 直接 | |
| 2024/1/15 | Common Stock | M行使選擇權處分 | −4,519 | $0.00 | $0 | 4,519 | 直接 | |
| 2024/1/15 | Common Stock | M行使選擇權處分 | −833 | $0.00 | $0 | 0 | 直接 | |
| 2024/1/15 | Common Stock | A公司授予取得 | +75,000 | $0.00 | $0 | 75,000 | 直接 | |
| 2024/1/15 | Common Stock | A公司授予取得 | +16,667 | $0.00 | $0 | 16,667 | 直接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F7
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On January 17, 2024, the Reporting Person filed a Form 4 reporting the vesting of restricted stock units ("RSU"s) between January 13, 2024 and January 15, 2024 and the sale of shares of common stock on January 16, 2024 to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs (the "Original Form 4"). Due to an inadvertent arithmetic error, the number of shares beneficially owned by the Reporting Person following the receipt of the RSUs that vested on January 13, 2024 was incorrectly reported, which error also impacted the beneficial ownership figures reported following the subsequent transactions reported in the Original Form 4. This Form 4/A is being filed to correct the number of shares held by the Reporting Person as of January 16, 2024 after all transactions reported in the Original Form 4.